Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Johnson & Johnson Starts Construction on $300 Million China Plant

publication date: Apr 18, 2014
Johnson & Johnson broke ground yesterday on a $300 million facility in the Xi'an High-tech Development Zone. For J&J, the new facility is its biggest single investment in a plant and its largest production facility (2.9 million square feet). It will house an innovation center for J&J's Asian supply chain, the largest production capacity for vaccines in Asia, and a registration center for foreign biomedical projects. Construction will be completed in 2018. More details....

Stock Symbol: (NYSE: JNJ)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital